Clinical Trial Update: Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the efficacy and safety of 177Lu-edotreotide peptide receptor radionuclide therapy in gastroenteropancreatic neuroendocrine tumo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• 177Lu-edotreotide (lutetium-177-edotreotide)

Snippet

Sponsor: ITM Solucin GmbH | Conditions: Neuroendocrine Tumors | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-06